Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
Authors
Keywords
Vactosertib, ALK5 inhibitor, Pharmacokinetics, First-in-human study, Solid tumors
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-13
DOI
10.1007/s10637-019-00835-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
- (2018) Srdan Verstovsek et al. HEMATOLOGICAL ONCOLOGY
- Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
- (2018) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Transforming growth factor-β: A therapeutic target for cancer
- (2017) Sulsal Haque et al. Human Vaccines & Immunotherapeutics
- Critical parameters in targeted drug development: the pharmacological audit trail
- (2016) Udai Banerji et al. SEMINARS IN ONCOLOGY
- TCR signaling intensity controls CD8+ T cell responsiveness to TGF-
- (2015) V. Arumugam et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
- (2014) Jordi Rodón et al. INVESTIGATIONAL NEW DRUGS
- Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent
- (2014) Cheng Hua Jin et al. JOURNAL OF MEDICINAL CHEMISTRY
- EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
- (2014) J. Y. Son et al. MOLECULAR CANCER THERAPEUTICS
- Early phase clinical trials to identify optimal dosing and safety
- (2014) Natalie Cook et al. Molecular Oncology
- Determining the optimal dose in the development of anticancer agents
- (2014) Ron H. J. Mathijssen et al. Nature Reviews Clinical Oncology
- Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy
- (2013) Yhun Yhong Sheen et al. Biomolecules & Therapeutics
- Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
- (2013) Ivelina Gueorguieva et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement
- (2013) Frederik E. Stuurman et al. CLINICAL PHARMACOKINETICS
- Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
- (2013) Jeong-Hwan Yoon et al. EMBO Molecular Medicine
- Formulation approaches in mitigating toxicity of orally administrated drugs
- (2013) Irina Kadiyala et al. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now